STAT+: Pfizer’s experimental RSV vaccine protects older adults in study

A vaccine Pfizer is developing protected older adults against the respiratory syncytial virus, or RSV, which is a common cause of hospitalization and death in the U.S., the company said Thursday.

The experimental vaccine, known as RSVpreF, is considered a key product in Pfizer’s pipeline of experimental drugs. Right now drug companies are close to launching several different products against RSV, focused on protecting both older adults and infants.

Continue to STAT+ to read the full story…

Read Original Article: STAT+: Pfizer’s experimental RSV vaccine protects older adults in study »